TAK-243
Based on 89 publication(s) in Google Scholar
TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 1450833-55-2
- Formula: C19H20F3N5O5S2
- Molecular Weight:519.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) TAK-243
More- Nature. 2026 Jan;649(8098):1032-1041. [Abstract]
- Nature. 2025 Jul;643(8073):1107-1116. [Abstract]
- Nature. 2025 Feb;638(8050):519-527. [Abstract]
- Nature. 2023 Jun;618(7964):394-401. [Abstract]
- Cancer Discov. 2025 Feb 7;15(2):363-381. [Abstract]
- Nat Cell Biol. 2026 Mar 13. [Abstract]
- Mol Cell. 2026 Jun 4;86(11):2173-2190.e11.
- Mol Cell. 2025 Mar 20:S1097-2765(25)00152-2. [Abstract]
- Mol Cell. 2022 Sep 15;82(18):3453-3467.e14. [Abstract]
- Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]
- Mol Cell. 2019 Aug 22;75(4):849-858.e8. [Abstract]
- ACS Nano. 2025 Feb 11;19(5):5659-5679. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2025 Oct 29;16(1):9554. [Abstract]
- Nat Commun. 2025 Sep 2;16(1):8182. [Abstract]
- Nat Commun. 2024 Jun 26;15(1):5409. [Abstract]
- Nat Commun. 2024 May 13;15(1):4026. [Abstract]
- Nat Commun. 2023 Jul 15;14(1):4227. [Abstract]
- Neuron. 2025 Aug 29:S0896-6273(25)00587-2. [Abstract]
- Nat Chem Biol. 2025 Apr;21(4):490-500. [Abstract]
- Nat Chem Biol. 2020 Nov;16(11):1199-1207. [Abstract]
- Theranostics. 2025 Mar 19;15(10):4526-4549. [Abstract]
- Theranostics. 2022 Aug 8;12(13):5949-5970. [Abstract]
- J Exp Clin Cancer Res. 2023 May 12;42(1):121. [Abstract]
- Sci Adv. 2026 Feb 6;12(6):eadz3483. [Abstract]
- J Exp Med. 2024 Jun 3;221(6):e20232132. [Abstract]
- Cell Commun Signal. 2019 Dec 26;17(1):171. [Abstract]
- EMBO J. 2026 Jan;45(1):261-277. [Abstract]
- EMBO J. 2025 Sep;44(17):4825-4866. [Abstract]
- EMBO J. 2025 Apr;44(8):2211-2231. [Abstract]
- EMBO J. 2025 Feb;44(4):1185-1219. [Abstract]
- EMBO J. 2024 Mar;43(6):904-930. [Abstract]
- Cancer Immunol Res. 2025 Jun 12. [Abstract]
- Neoplasia. 2022 Oct:32:100823. [Abstract]
- JHEP Rep. 2025 Jul 31;7(11):101534. [Abstract]
- Cell Chem Biol. 2026 Apr 16;33(4):553-570.e5. [Abstract]
- Cell Rep. 2025 Nov 25;44(12):116602. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Cell Rep. 2024 Jul 18;43(8):114522. [Abstract]
- J Med Chem. 2022 Jan 13;65(1):747-756. [Abstract]
- Commun Med (Lond). 2025 Apr 26;5(1):140. [Abstract]
- Front Immunol. 2022 Feb 9;13:815936. [Abstract]
- Chem Biol Interact. 2026 Mar 18:112045. [Abstract]
- Cells. 2024 Apr 25;13(9):747. [Abstract]
- Commun Biol. 2024 Dec 31;7(1):1719. [Abstract]
- PLoS Pathog. 2025 Oct 14;21(10):e1013593. [Abstract]
- Int J Mol Sci. 2024 Nov 26;25(23):12696. [Abstract]
- PLoS Pathog. 2024 Jun 20;20(6):e1012329. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- J Biol Chem. 2022 Jun;298(6):102026. [Abstract]
- J Biol Chem. 2019 Nov 8;294(45):16511-16524. [Abstract]
- J Virol. 2022 Nov 9;96(21):e0119522. [Abstract]
- Cytokine. 2025 Oct:194:156989. [Abstract]
- Breast Cancer Res Treat. 2023 Apr;198(3):607-621. [Abstract]
- Carcinogenesis. 2025 Aug 18:bgaf040. [Abstract]
- Biochem Biophys Res Commun. 2023 Nov 19:682:27-38. [Abstract]
- Biosci Biotechnol Biochem. 2024 Nov 22;88(12):1432-1441. [Abstract]
- bioRxiv. 2026 Jun 9:2026.06.01.729344. [Abstract]
- bioRxiv. 2026 May 29:2026.05.26.727520. [Abstract]
- bioRxiv. 2026 May 14:2026.05.12.724395. [Abstract]
- Johannes Gutenberg University Mainz. 2026.
- bioRxiv. 2026 Mar 17:2026.03.13.711603. [Abstract]
- bioRxiv. 2026 Mar 27.
- University of Montreal. 2025.
- bioRxiv. 2025 Oct 21.
- University of California. 2025.
- University of California. 2025.
- bioRxiv. 2025 Sep 12.
- bioRxiv. 2025 Aug 09.
- University of Toronto. 2025.
- bioRxiv. 2025 May 15:2025.05.10.653233. [Abstract]
- bioRxiv. 2025 May 17.
- bioRxiv. 2024 November 10.
- Res Sq. 2024 Nov 25.
- bioRxiv. 2024 Sep 27:2024.09.25.615094. [Abstract]
- bioRxiv. 2024 September 10.
- bioRxiv. 2024 August 28.
- bioRxiv. 2024 June 12.
- bioRxiv. 2024 Apr 26.
- bioRxiv. 2024 Jan 28.
- bioRxiv. 2023 Dec 9.
- bioRxiv. 2023 Oct 2.
- bioRxiv. 2023 Sep 21.
- bioRxiv. 2023 Sep 16:2023.09.15.556420. [Abstract]
- bioRxiv. 2023 Jul 19.
- Patent. US20230124700A1.
- Research Square Preprint. 2021 Aug.
- bioRxiv. 2021 Jan 20.
- Research Square Preprint. 2020 Jul.
-
IHC
-
WB
-
RT-PCR
-
WB
-
WB
Biological Activity
IC50: 1 nM (UBA1)[1]
TAK-243 shows anti-proliferative effect on a panel of cell lines derived from hematologic and solid tumors with variable EC50 values that ranged from 0.006 μM to 1.31 μM[1].
?
TAK-243 reduces growth and viability of human AML cell lines (OCI-AML2, TEX, U937 and NB4) in a concentration- and time-dependent manner with IC50s ranging from 15-40 nM after treatment for 48 hours[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1450833-55-2
-
Appearance Solid
-
Molecular Weight 519.52
-
Formula C19H20F3N5O5S2
-
Color White to light yellow
-
SMILES
O=S(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC2=CC=NC3=CC(C4=CC=CC(SC(F)(F)F)=C4)=NN23)C1)(N)=O
-
Synonyms
MLN7243
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (89)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jan;649(8098):1032-1041. PMID: 41299171 -
Nature
2025 Jul;643(8073):1107-1116. PMID: 40468084 -
Nature
2025 Feb;638(8050):519-527. PMID: 39880951 -
Nature
2023 Jun;618(7964):394-401. PMID: 37225996
TAK-243 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):394-401. [Abstract]
The E1 inhibitor decreased the flux of ER-phagy in mCherry-GFP-FAM134B-WT cells induced with Torin 1. ER-phagy flux was quantified as the ratio between mCherry+/GFP– and mCherry+/GFP+ puncta, quantified using CQ1 software. Data are means ± s.d. of n = 5 independent experiments in which the number of cells per condition were: (DMSO) 837 basal, 1072 BafA1, 1038 Torin1, 966 BafA1+Torin1. Number of cells (10 µM TAK243): 729 basal, 1174 BafA1, 1060 Torin1, 1121 Torin1+BafA1
TAK-243 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):394-401. [Abstract]
Cells were treated with DMSO (control) or 10 µM TAK243 for 1, 2 and 4 h before TUBE-2 pulldown assays. Endogenous ubiquitination of FAM134B was detected by western blot (n = 1 experiment). The results showed that TAK243, a potent inhibitor of the ubiquitin (Ub)-activating enzyme, abolished endogenous FAM134B ubiquitination.
TAK-243 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):394-401. [Abstract]
Cycloheximide (50 µg/mL) chase for 0–6 h in HeLa cells with or without 10 µM TAK243. Detergent-soluble extracts were analysed by western blot with antibodies against FAM134B, UbP4D1 and vinculin.
-
Cancer Discov
2025 Feb 7;15(2):363-381. PMID: 39540840
TAK-243 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2025 Feb 7;15(2):363-381. [Abstract]
Left: immunoblot analysis assessing JAK1 expression in Myc-CaP cells that received knockout of Jak1 (Jak1 KO). Cells receiving nontargeting sgRNA were used as control. Right: surface expression of MHC-I measured by flow cytometry in the indicated cells treated with or without 50 nmol/L TAK-243 and stimulated with or without IFN-γ. Data were acquired from technical triplicates, representative of two independent experiments.
-
Nat Cell Biol
An SP110-SP100 axis is a critical regulator of promyelocytic leukaemia body dynamics and mitotic fidelity. [Abstract]2026 Mar 13. PMID: 41826696 -
-
Mol Cell
UbiREAD deciphers proteasomal degradation code of homotypic and branched K48 and K63 ubiquitin chains. [Abstract]2025 Mar 20:S1097-2765(25)00152-2. PMID: 40132582 -
Mol Cell
TMUB1 is an endoplasmic reticulum-resident escortase that promotes the p97-mediated extraction of membrane proteins for degradation. [Abstract]2022 Sep 15;82(18):3453-3467.e14. PMID: 35961308 -
Mol Cell
RNF126-Mediated Reubiquitination Is Required for Proteasomal Degradation of p97-Extracted Membrane Proteins. [Abstract]2020 Jul 16;79(2):320-331.e9. PMID: 32645369
TAK-243 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]
Purified BAG6-ABCG2-F208S complex was added into DMSO- or TAK-243 (MLN7243)-treated RRL and incubated at 30 ℃ for indicated times. Reactions were stopped and directly analyzed by immunoblotting for ABCG2-F208S.
-
Mol Cell
Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. [Abstract]2019 Aug 22;75(4):849-858.e8. PMID: 31442425 -
ACS Nano
Emerging of Ultrafine Membraneless Organelles as the Missing Piece of Nanostress: Mechanism of Biogenesis and Implications at Multilevels. [Abstract]2025 Feb 11;19(5):5659-5679. PMID: 39882824
TAK-243 purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Feb 11;19(5):5659-5679. [Abstract]
TAK-243/Spautin-1 groups results consistently support a positive correlation between the activity of HSP90, ubiquitination, and proteasome system with the disassembly of NSGs.
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Nanomaterial signatures program biomolecular condensates via triphasic separation for chemoplasticity remodeling. [Abstract]2025 Oct 29;16(1):9554. PMID: 41162367 -
Nat Commun
2025 Sep 2;16(1):8182. PMID: 40897715 -
Nat Commun
2024 Jun 26;15(1):5409. PMID: 38926334 -
Nat Commun
Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants. [Abstract]2024 May 13;15(1):4026. PMID: 38740822 -
Nat Commun
HIV-1 promotes ubiquitination of the amyloidogenic C-terminal fragment of APP to support viral replication. [Abstract]2023 Jul 15;14(1):4227. PMID: 37454116
TAK-243 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 15;14(1):4227. [Abstract]
Ubiquitination inhibitor TAK-243 (100 nM; 24 h) stabilizes exogenous Flag-C99 but not C83-V5 in HEK293A cells transfected with either empty vector control (pcDNA3.1) or JR-CSF.
-
Neuron
2025 Aug 29:S0896-6273(25)00587-2. PMID: 40902597 -
Nat Chem Biol
2025 Apr;21(4):490-500. PMID: 39215100 -
Nat Chem Biol
2020 Nov;16(11):1199-1207. PMID: 32747809 -
Theranostics
Targeting USP11 counteracts SFTPCI73T -associated interstitial lung disease in hiPSCs-derived alveolar organoids and in vivo models. [Abstract]2025 Mar 19;15(10):4526-4549. PMID: 40225577 -
Theranostics
CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. [Abstract]2022 Aug 8;12(13):5949-5970. PMID: 35966591 -
J Exp Clin Cancer Res
CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis. [Abstract]2023 May 12;42(1):121. PMID: 37170124 -
Sci Adv
2026 Feb 6;12(6):eadz3483. PMID: 41650254 -
J Exp Med
2024 Jun 3;221(6):e20232132. PMID: 38625151 -
Cell Commun Signal
2019 Dec 26;17(1):171. PMID: 31878945 -
EMBO J
Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation. [Abstract]2026 Jan;45(1):261-277. PMID: 41326691 -
EMBO J
2025 Sep;44(17):4825-4866. PMID: 40691417 -
EMBO J
2025 Apr;44(8):2211-2231. PMID: 40000907 -
EMBO J
RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis. [Abstract]2025 Feb;44(4):1185-1219. PMID: 39762645 -
EMBO J
Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. [Abstract]2024 Mar;43(6):904-930. PMID: 38337057 -
Cancer Immunol Res
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies. [Abstract]2025 Jun 12. PMID: 40506249 -
Neoplasia
SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy. [Abstract]2022 Oct:32:100823. PMID: 35907292 -
JHEP Rep
2025 Jul 31;7(11):101534. PMID: 41127880 -
Cell Chem Biol
IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes. [Abstract]2026 Apr 16;33(4):553-570.e5. PMID: 41923618 -
Cell Rep
Harnessing the E3 ligase SPOP for targeted degradation of the NUP98::KDM5A fusion oncoprotein. [Abstract]2025 Nov 25;44(12):116602. PMID: 41307993 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Cell Rep
2024 Jul 18;43(8):114522. PMID: 39028621 -
J Med Chem
2022 Jan 13;65(1):747-756. PMID: 34965125 -
Commun Med (Lond)
Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. [Abstract]2025 Apr 26;5(1):140. PMID: 40287552 -
Front Immunol
ATG Ubiquitination Is Required for Circumsporozoite Protein to Subvert Host Innate Immunity Against Rodent Malaria Liver Stage. [Abstract]2022 Feb 9;13:815936. PMID: 35222391 -
Chem Biol Interact
Damage to newly synthesized proteins is a major cause of Cd(II) toxicity counteracted by proteasomes and integrated stress response in human cells. [Abstract]2026 Mar 18:112045. PMID: 41861982 -
Cells
TurboID-Based IRE1 Interactome Reveals Participants of the Endoplasmic Reticulum-Associated Protein Degradation Machinery in the Human Mast Cell Leukemia Cell Line HMC-1.2. [Abstract]2024 Apr 25;13(9):747. PMID: 38727283 -
Commun Biol
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors. [Abstract]2024 Dec 31;7(1):1719. PMID: 39741170 -
PLoS Pathog
UBXN7 facilitates SARS-CoV-2 replication via inhibiting the K48-linked ubiquitination of viral N protein. [Abstract]2025 Oct 14;21(10):e1013593. PMID: 41086194 -
Int J Mol Sci
Ubiquitin-Activating Enzyme E1 (UBA1) as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Insights into Immune Infiltration and Functional Implications. [Abstract]2024 Nov 26;25(23):12696. PMID: 39684409 -
PLoS Pathog
Human coronavirus NL63 nsp1 induces degradation of RNA polymerase II to inhibit host protein synthesis. [Abstract]2024 Jun 20;20(6):e1012329. PMID: 38900816 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
J Biol Chem
Binding of the erlin1/2 complex to the third intralumenal loop of IP3R1 triggers its ubiquitin-proteasomal degradation. [Abstract]2022 Jun;298(6):102026. PMID: 35568199 -
J Biol Chem
Acute unfolding of a single protein immediately stimulates recruitment of ubiquitin protein ligase E3C (UBE3C) to 26S proteasomes. [Abstract]2019 Nov 8;294(45):16511-16524. PMID: 31375563 -
J Virol
Nonlytic Quasi-Enveloped Hepatovirus Release Is Facilitated by pX Protein Interaction with the E3 Ubiquitin Ligase ITCH. [Abstract]2022 Nov 9;96(21):e0119522. PMID: 36286484 -
Cytokine
2025 Oct:194:156989. PMID: 40628045 -
Breast Cancer Res Treat
Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs. [Abstract]2023 Apr;198(3):607-621. PMID: 36847915 -
Carcinogenesis
Core Transcriptional Regulatory Circuit-Regulated IGF2BP3 Stabilizes E2F2 mRNA via m6A Modification in Neuroblastoma. [Abstract]2025 Aug 18:bgaf040. PMID: 40823720 -
Biochem Biophys Res Commun
βTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells. [Abstract]2023 Nov 19:682:27-38. PMID: 37801987 -
Biosci Biotechnol Biochem
Synergistic effect of cerium chloride and calcium chloride alters calcium signaling in keratinocytes to promote epidermal differentiation. [Abstract]2024 Nov 22;88(12):1432-1441. PMID: 39333009 -
bioRxiv
2026 Jun 9:2026.06.01.729344. PMID: 42282570 -
bioRxiv
2026 May 29:2026.05.26.727520. PMID: 42244578 -
bioRxiv
2026 May 14:2026.05.12.724395. PMID: 42182270 -
-
bioRxiv
Ischemia-Induced Post-Translational Modifications of GLT-1 Mediate Aberrant Trafficking and Impaired Glutamate Uptake. [Abstract]2026 Mar 17:2026.03.13.711603. PMID: 41890068 -
-
-
-
-
-
-
-
-
bioRxiv
2025 May 15:2025.05.10.653233. PMID: 40463067 -
-
-
-
bioRxiv
2024 Sep 27:2024.09.25.615094. PMID: 39386645 -
-
-
-
-
-
-
-
-
bioRxiv
Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states. [Abstract]2023 Sep 16:2023.09.15.556420. PMID: 37745470 -
-
-
-
-
Solvent & Solubility
DMSO : 50 mg/mL (96.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Normal keratinocytes (normal human keratinocytes (NHK) and recessive dystrophic epidermolysis bullosa keratinocytes (RDEBK)) and cSCC cell lines are seeded into 96 well plates and live cell number and cell death are analysed with an IncuCyte ZOOM real-time imager using the CellTox Green Cytotoxicity Assay. Relative EC50 values are determined using GraphPad Prism. For clonogenic assays cells are seeded into six well plates. Inhibitors (e.g., TAK-243; 0.01, 0.1, 1, and 10 μM) are added for the indicated times and then cells are maintained in drug-free medium for up to 2 weeks to allow colony formation. Colonies are fixed in 10% methanol, 10% acetic acid and stained with crystal violet[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
The preclinical efficacy and toxicity of TAK-243 are assessed in mouse models of AML. OCI-AML2 cells are injected subcutaneously (sc) into SCID mice, and when tumors are palpable, mice are treated with TAK-243 (20 mg/kg sc twice weekly). As an additional model, primary AML cells from 2 patients are injected into the femurs of NOD-SCID mice. Two weeks after injection, mice are treated with TAK-243 (20 mg/kg sc twice weekly). After 3 weeks of treatment, mice ae sacrificed, and AML engraftment in the non-injected femur is measured by flow cytometry[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9249 mL | 9.6243 mL | 19.2485 mL | 48.1213 mL |
| 5 mM | 0.3850 mL | 1.9249 mL | 3.8497 mL | 9.6243 mL | |
| 10 mM | 0.1925 mL | 0.9624 mL | 1.9249 mL | 4.8121 mL | |
| 15 mM | 0.1283 mL | 0.6416 mL | 1.2832 mL | 3.2081 mL | |
| 20 mM | 0.0962 mL | 0.4812 mL | 0.9624 mL | 2.4061 mL | |
| 25 mM | 0.0770 mL | 0.3850 mL | 0.7699 mL | 1.9249 mL | |
| 30 mM | 0.0642 mL | 0.3208 mL | 0.6416 mL | 1.6040 mL | |
| 40 mM | 0.0481 mL | 0.2406 mL | 0.4812 mL | 1.2030 mL | |
| 50 mM | 0.0385 mL | 0.1925 mL | 0.3850 mL | 0.9624 mL | |
| 60 mM | 0.0321 mL | 0.1604 mL | 0.3208 mL | 0.8020 mL | |
| 80 mM | 0.0241 mL | 0.1203 mL | 0.2406 mL | 0.6015 mL |